PE-22-28 FAQ: common questions answered
An experimental mood peptide studied in mice, with no human trials found.
Also called: PE 22-28, PE22-28, Mini-spadin, GVSWGLR.
Nootropic peptides · Shortened spadin analogue; experimental TREK-1 potassium-channel modulator · Evidence: Animal studies only.
- Is PE-22-28 FDA-approved? No FDA approval or label found. No compound-specific warning letter located. An unapproved research product has no FDA-approved prescribing instructions.
- How do people take it? Under the skin, once daily. Source: reported by users, not an established dose.
- What's the difference between PE-22-28 and Selank? PE-22-28: an experimental mood peptide studied in mice, with no human trials found. Selank: a Russian nasal anxiety peptide with uncertain long-term benefit and safety. Why people pair them: users combine nasal formulations hoping for calmer mood and less anxiety. No human trial has tested this combination.
- Can I take it with Selank? Users combine nasal formulations hoping for calmer mood and less anxiety. No human trial has tested this combination. Reported benefit cannot be assigned to either ingredient; combination safety and spray delivery are untested. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Falls under the rule for unapproved pharmacological substances. This applies the S0 rule; PE-22-28 is not named individually.
- How long does a mixed vial last? No validated mixed-solution expiry, refrigerator stability or freeze-thaw data was found.
Related to PE-22-28
- Semax: A Russian nasal peptide with limited human evidence for brain and nerve effects.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- Dihexa: An experimental memory compound with disputed animal research and no established human dose.
- P21: An experimental memory peptide with animal research and no established human dose or safety profile.
- Cerebrolysin: An injectable pig brain mixture with mixed stroke, brain-injury and dementia evidence.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Drugs@FDA: FDA-Approved Drugs, US Food and Drug Administration
- Frequently Asked Questions About Suicide, National Institute of Mental Health
- Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study., Ashraf AR et al. · Journal of medical Internet research · 2024
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.